Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 2/20 | 0.41 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.36 |
| ▸ | FYN | P06241 | 2/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.35 |
| ▸ | MTOR | P42345 | 2/20 | 0.35 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.35 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.35 |
| ▸ | FLT3 | P36888 | 3/20 | 0.34 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | NRAS | P01111 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3022761 | 0.81 | FYN (0.48) | GRM5KCNH2FYNMKNK1MKNK2 | |
| SCHEMBL3033111 | 0.79 | ACVR1B (0.41) | TGFBR1ACVR1BGRM5KCNH2FYN | |
| SCHEMBL3026528 | 0.79 | PIK3CA (0.44) | KCNH2PIK3CAMTORFLT3 | |
| SCHEMBL3034092 | 0.79 | GRM5 (0.46) | TGFBR1ACVR1BGRM5IRAK4FYN | |
| SCHEMBL3033533 | 0.78 | MKNK1 (0.46) | FYNMKNK1MKNK2 | |
| SCHEMBL3030851 | 0.78 | GRM5 (0.41) | TGFBR1ACVR1BGRM5KCNH2FYN | |
| SCHEMBL3033094 | 0.77 | FYN (0.44) | GRM5FYNMKNK1MKNK2ADORA2A | |
| SCHEMBL3025964 | 0.76 | FYN (0.52) | KCNH2FYNPIK3CA | |
| SCHEMBL3027037 | 0.75 | MAPK8 (0.43) | TGFBR1ACVR1BGRM5KCNH2IRAK4 | |
| SCHEMBL3021775 | 0.74 | PIK3CA (0.45) | GRM5KCNH2PIK3CAMTORFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367662-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-02-05 | — | — | US | disclosed |
| EP-2212323-B1 | IMIDAZO [1,2-A] PYRIDINE DERIVATIVES USEFUL AS ALK INHIBITORS | NOVARTIS AG (CH) | 2012-08-15 | — | — | EP | disclosed |
| US-20100210641-A1 | Organic Compounds | NOVARTIS AG (CH) | 2010-08-19 | — | — | US | disclosed |
| EP-2212323-A2 | IMIDAZO [1,2-A] PYRIDINE DERIVATIVES USEFUL AS ALK INHIBITORS | Novartis AG (CH) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009050183-A2 | IMIDAZO [1, 2-A] PYRIDINE DERIVATIVES USEFUL AS ALK INHIBITORS | NOVARTIS AG (CH) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210641-A1 | Organic Compounds | ALK, ACVR1, ACVRL1 | TGFBR1 11/4885ACVR1B 9/4885GRM5 958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.